The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2023

Filed:

Aug. 10, 2016
Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Kornelia Polyak, Brookline, MA (US);

Shaokun Shu, Brookline, MA (US);

James E. Bradner, Weston, MA (US);

Charles Yang Lin, Houston, TX (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/551 (2006.01); A61K 31/5415 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01); A61K 31/137 (2006.01);
U.S. Cl.
CPC ...
A61K 31/551 (2013.01); A61K 31/137 (2013.01); A61K 31/5415 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/57415 (2013.01);
Abstract

The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.


Find Patent Forward Citations

Loading…